Positive and negative treatment expectations and their effects on placebo analgesia and nocebo hyperalgesia, and their stability over time
- Conditions
- pain perceptionhealthy participants
- Registration Number
- DRKS00029228
- Lead Sponsor
- niversitätsklinikum EssenKlinik für Neurologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 112
Age: 18-40 years, consent to study, fluent German skills, healthy
Alcohol consumption one day before trial day 2 and/or 3;
Alcohol consumption on trial day 1-3;
Substance/drug use in the last 4 weeks;
Medication use in the last 7 days (except hormonal contraceptives);
Use of anticoagulant or pain medications in the last 24 hours;
Known neurological, internal, psychological, as well as skin and cold-associated diseases;
Allergies (contact allergies);
Participation in an electrostimulation or heat stimulation study in the last 6 months;
Color blindness or red-green deficiency;
Surgical procedures in the last 6 months;
Injuries/scars on the forearms;
Skin damage (e.g. sunburn) on the forearms;
Limited visual acuity or uncorrected visual acuity;
Restricted hearing;
Acute infections
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The extent of placebo analgesia and nocebo hyperalgesia (difference in subjective pain intensity as an interaction between the experimental condition (placebo vs. nocebo vs. control) on the day of the conditioning phase.
- Secondary Outcome Measures
Name Time Method The extent of placebo analgesia and nocebo hyperalgesia one week after the conditioning phase;<br><br>The expectation of pain intensity on the day of conditioning and one week later compared to baseline (before conditioning);<br><br>Exploratory outcome measures are treatment experience and tolerability, genetic predispositions (saliva sample), tolerability and side effects on day 1, 2 and 8 (GASE), psychometric predictors (prior experience with placebo treatment, somatosensory amplification (Somatosensory Amplification Scale, SSAS), perceived stress (Perceived Stress Scale, PSS), Anxiety and depression as a state (State)/current state (State-Trait-Anxiety-Depression Inventory, STADI State), Anxiety and depression as a trait (Trait)/general state anxiety and depression (STADI Trait), Fear of pain (Fear of Pain Questionnaire-III (FPQ-III)), Catastrophizing thoughts related to pain (Pain Catastrophizing Scale, PCS), Personality factors (10-item Big Five Inventory)).